...
首页> 外文期刊>Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society >Time course of lewisite-induced skin lesions and inflammatory response in the SKH-1 hairless mouse model.
【24h】

Time course of lewisite-induced skin lesions and inflammatory response in the SKH-1 hairless mouse model.

机译:在SKH-1无毛小鼠模型中,路易斯酸引起的皮肤损伤和炎症反应的时程。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Data on the toxicity of lewisite (L), a vesicant chemical warfare agent, are scarce and conflicting, and the use of the specific antidote is not without drawbacks. This study was designed to evaluate if the SKH-1 hairless mouse model was suitable to study the L-induced skin injuries. We studied the progression of lesions following exposure to L vapors for 21 days using paraclinical parameters (color, transepidermal water loss (TEWL), and biomechanical measurements), histological assessments, and biochemical indexes of inflammation. Some data were also obtained over 27 weeks. The development of lesions was similar to that reported in other models. The TEWL parameter appeared to be the most appropriate index to follow their progression. Histological analysis showed inflammatory cell infiltration and microvesications at day 1 and a complete wound closure by day 21. Biochemical studies indicated a deregulation of the levels of several cytokines and receptors involved in inflammation. An increase in the quantity of pro-matrix metalloproteinases 2 and 9 was shown as observed in other models. This suggests that the SKH-1 mouse model is relevant for the investigation of the physiopathological process of skin lesions induced by L and to screen new treatment candidates.
机译:关于泡腾剂(L)(一种发泡剂的化学战剂)的毒性数据很少,而且相互矛盾,使用特定的解毒剂并非没有缺点。这项研究旨在评估SKH-1无毛小鼠模型是否适合研究L诱导的皮肤损伤。我们使用临床旁参数(颜色,表皮水分流失(TEWL)和生物力学测量),组织学评估以及炎症的生化指标研究了暴露于L蒸汽21天后的病变进展。在27周内也获得了一些数据。病变的发展与其他模型中报道的相似。 TEWL参数似乎是跟随其进展的最合适的指标。组织学分析显示第1天发炎细胞浸润和微囊泡形成,第21天伤口完全闭合。生化研究表明,参与炎症的几种细胞因子和受体水平失调。如在其他模型中观察到的,前基质金属蛋白酶2和9的数量增加。这表明SKH-1小鼠模型与L诱导的皮肤损伤的生理病理过程的研究以及筛选新的治疗候选物有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号